Online Now: Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells dlvr.it/TCjSGV

Learn from Mayo Clinic experts how the power of the body's immune system may be harnessed to fight cancer. Join @YILinMDPhD and Hong Qin, M.D., Ph.D., at the Mayo Clinic RegenBio Summit 24, Dec. 9-11 in Ponte Vedra Beach, Florida. Register here: mayocl.in/4e9wxgD

Mayo’s Anna-Maria and Stephen Kellen Building for research was intentionally designed to promote innovation, prioritize safety, and foster collaboration. Read more: bit.ly/3BqT6PP

Former U.S. president, cancer survivor, and immunotherapy advocate, Jimmy Carter, celebrates his 100th birthday today! Discover how President Carter ushered immunotherapy into the mainstream, and explore the positive ripple effects, in our new blog post: bit.ly/3BtrYQg

Solid cancer-directed CAR T-cell therapy that attacks both tumor and myeloid cells via targeting PD-L1, a potential cell therapy for GBM. Great job at Dr. HongQinlab. sciencedirect.com/science/articl…

Congratulations Joanina! You lit a little candle in the dark.#Tcellresilience .Joanina Gicobi, Ph.D. (She/Her)⁩

The discovery of T cell receptor (TCR) was a major breakthrough and paved the way for significant advances in the fields of T cell biology and immunotherapy.

Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative therapy! TILs have the potential to CURE- complete responders from National Cancer Institute with 10 year melanoma-specific survival of 96%. Unmodified TILs are just a starting

PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity biorxiv.org/cgi/content/sh… #biorxiv_immuno

PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity biorxiv.org/content/10.110… Haidong Dong Zhiming Mao

Happy to share my thesis work as preprint in bioRxiv Immunology ! We found an interesting role of PD-1 in regulating the effector cytotoxic and exhaustion potential of thymic mature CD8+ T cells, which impacts the maintenance of peripheral tumor immunity. biorxiv.org/content/10.110…

Mayo’s Cancer CARE Beyond Walls program is transforming the cancer treatment experience for patients to offer more convenience and a better quality of life. Dr. Roxana Dronca shares more: mayocl.in/3CtSDgI

A key feature of resilient T cells is revealed: Lysosomal NKG7 restrains mTORC1 activity to promote CD8+ T cell durability and tumor control. rdcu.be/d9RXx Congratulations!!! June, Dan, Henrique and all authors!!

Haidong Dong Nice paper! Wanted to share a poster from ASH 2023 Corvus Pharmaceutical $CRVS oral ITK inhibitor soquelitinib induces #NKG7 which reduces mTORC1 and promotes CD8+ Tcell memory, reduces T-cell exhaustion genes (PD-1, LAG-3, TIM-3). soquelitinib in Ph3 trial for PTCL, starting

What is cancer immunotherapy ? A brief introduction of that at Mayo Clinic. cancerblog.mayoclinic.org/2025/02/26/wha…

T cell longevity, a new role of NKG7 there. newsnetwork.mayoclinic.org/discussion/may…

Speaker Spotlight for Mayo Clinic RNA Discoveries and Therapeutics Conference on our FL campus on May 30-31, 2025, livestream option. Excited to have Haidong Dong from Mayo Clinic as a presenter. Don’t forget to register and submit abstracts. lnkd.in/gtqwsy55 Dr. Alfredo Quiñones-Hinojosa

Our new humanized both PD-1 and PD-L1 mice are now available at the Jax lab with an RRID. Thank you all for your interest in use of this mouse model to shorten preclinical and clinical space for targeting this pathway. The link for strain details: jax.org/strain/040677

Our new review article is online today: A Dual Role for NKG7 in T-cell Cytotoxicity and Longevity aacrjournals.org/cancerimmunolr…